| Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, Interest Expense, Income Tax Expense and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales, depreciation and amortization, operating profit, interest expense, and income tax expense for the three months ended February 28, 2021 and February 29, 2020:
|
|
|
For the three
months ended
February 28,
2021
|
|
|
For the three
months ended
February 29,
2020
|
|
|
Net revenue
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
6,738,631
|
|
|
$
|
7,406,288
|
|
|
PrepaCyte®-CB
|
|
|
38,000
|
|
|
|
60,407
|
|
|
Public cord blood banking
|
|
|
83,986
|
|
|
|
154,079
|
|
|
Total net revenue
|
|
$
|
6,860,617
|
|
|
$
|
7,620,774
|
|
|
Cost of sales
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
1,640,015
|
|
|
$
|
2,055,075
|
|
|
PrepaCyte®-CB
|
|
|
34,880
|
|
|
|
41,117
|
|
|
Public cord blood banking
|
|
|
337,302
|
|
|
|
406,952
|
|
|
Total cost of sales
|
|
$
|
2,012,197
|
|
|
$
|
2,503,144
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
14,368
|
|
|
$
|
37,327
|
|
|
PrepaCyte®-CB
|
|
|
6,895
|
|
|
|
6,894
|
|
|
Public cord blood banking
|
|
|
—
|
|
|
|
—
|
|
|
Total depreciation and amortization
|
|
$
|
21,263
|
|
|
$
|
44,221
|
|
|
Operating income
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
1,492,353
|
|
|
$
|
1,489,548
|
|
|
PrepaCyte®-CB
|
|
|
(3,777
|
)
|
|
|
12,396
|
|
|
Public cord blood banking
|
|
|
(253,315
|
)
|
|
|
(252,874
|
)
|
|
Total operating income
|
|
$
|
1,235,261
|
|
|
$
|
1,249,070
|
|
|
Interest expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
280,219
|
|
|
$
|
365,299
|
|
|
PrepaCyte®-CB
|
|
|
—
|
|
|
|
—
|
|
|
Public cord blood banking
|
|
|
—
|
|
|
|
—
|
|
|
Total interest expense
|
|
$
|
280,219
|
|
|
$
|
365,299
|
|
The following table shows the assets by segment as of February 28, 2021 and November 30, 2020:
|
|
|
As of
February 28,
2021
|
|
|
As of
November 30,
2020
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
93,405,068
|
|
|
$
|
34,215,780
|
|
|
PrepaCyte®-CB
|
|
|
235,248
|
|
|
|
302,683
|
|
|
Public cord blood banking
|
|
|
11,624,145
|
|
|
|
11,681,631
|
|
|
Total assets
|
|
$
|
105,264,461
|
|
|
$
|
46,200,094
|
|
|